TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ARTSS-2: A Pilot, Phase 2b, Randomized, Multi-center Trial of Argatroban in Combination With Recombinant Tissue Plasminogen Activator for Acute Stroke
Brief Summary: Randomized controlled clinical trial to estimate overall treatment benefit (improvement in disability) among stroke patients treated with rt-PA who are randomized to also receive either low-dose Argatroban, high-dose Argatroban or neither.


Options:
A: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: placebo | Arm Label: Rivaroxaban 5mg; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban, Drug: placebo | Arm Label: rivaroxaban 10mg; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban, Drug: placebo | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban 5mg, rivaroxaban 10mg | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Rivaroxaban 5mg, aspirin, rivaroxaban 10mg
B: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
C: Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): N/A
D: Arm Label: Low dose Argatroban + rt-PA (alteplase); Type: EXPERIMENTAL; Interventions: Drug: Low Dose Argatroban, Drug: rt-PA (alteplase) | Arm Label: High dose Argatroban + rt-PA (alteplase); Type: EXPERIMENTAL; Interventions: Drug: High Dose Argatroban, Drug: rt-PA (alteplase) | Arm Label: rt-PA (alteplase); Type: ACTIVE_COMPARATOR; Interventions: Drug: rt-PA (alteplase) | Intervention Type: DRUG; Name: Low Dose Argatroban; Assigned to Arm(s): Low dose Argatroban + rt-PA (alteplase) | Intervention Type: DRUG; Name: High Dose Argatroban; Assigned to Arm(s): High dose Argatroban + rt-PA (alteplase) | Intervention Type: DRUG; Name: rt-PA (alteplase); Assigned to Arm(s): High dose Argatroban + rt-PA (alteplase), Low dose Argatroban + rt-PA (alteplase), rt-PA (alteplase)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis
Brief Summary: This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.


Options:
A: Arm Label: CP-690,550 5 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,500 5 mg | Arm Label: CP-690,550 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 10 mg | Intervention Type: DRUG; Name: CP-690,500 5 mg; Assigned to Arm(s): CP-690,550 5 mg | Intervention Type: DRUG; Name: CP-690,550 10 mg; Assigned to Arm(s): CP-690,550 10 mg
B: Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CP-690,550 5 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP690,550 | Arm Label: CP-690,550 10 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator | Intervention Type: DRUG; Name: CP690,550; Assigned to Arm(s): CP-690,550 5 mg Arm | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 10 mg Arm
C: Arm Label: tofacitinib 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: tofacitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tofacitinib; Assigned to Arm(s): tofacitinib 10 mg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effectiveness of Physical Therapy Program to Treat Rotator Cuff Disorders Among Nursing Professionals According to Indicators of Quality of Life and Job Satisfaction
Brief Summary: The program of stretching, strengthening and proprioception is more effective than stretching and strengthening program in nursing, with rotator cuff disorder, according to indicators of quality of life and job satisfaction.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Physical therapy method called Supervised Exercises | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radial Extracorporeal Shockwave Therapy | Intervention Type: PROCEDURE; Name: Physical therapy method called Supervised Exercises; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Radial Extracorporeal Shockwave Therapy; Assigned to Arm(s): B
B: Arm Label: PT progressive exercises; Type: EXPERIMENTAL; Interventions: Procedure: Exercise program | Arm Label: Movement exercises neck and shoulder; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Exercise program, Procedure: Movement exercises | Intervention Type: PROCEDURE; Name: Exercise program; Assigned to Arm(s): Movement exercises neck and shoulder, PT progressive exercises | Intervention Type: PROCEDURE; Name: Movement exercises; Assigned to Arm(s): Movement exercises neck and shoulder
C: Arm Label: No proprioception; Type: ACTIVE_COMPARATOR; Interventions: Other: Control, no Proprioception | Arm Label: Proprioceptive exercises; Type: EXPERIMENTAL; Interventions: Other: Experimental, Proprioceptive exercises | Intervention Type: OTHER; Name: Control, no Proprioception; Assigned to Arm(s): No proprioception | Intervention Type: OTHER; Name: Experimental, Proprioceptive exercises; Assigned to Arm(s): Proprioceptive exercises
D: Arm Label: Manual Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Manual Physical Therapy | Arm Label: Corticosteroid Injection (Subacromial); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Corticosteroid Injection | Intervention Type: PROCEDURE; Name: Manual Physical Therapy; Assigned to Arm(s): Manual Physical Therapy | Intervention Type: PROCEDURE; Name: Corticosteroid Injection; Assigned to Arm(s): Corticosteroid Injection (Subacromial)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.
Brief Summary: Compare safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with primary safety variables including spontaneous reports of Adverse Events (AEs), withdrawal of subjects due to AEs, reporting of Serious AEs (SAEs).


Options:
A: Arm Label: Zonisamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zonisamide | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Zonisamide | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine
B: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A
C: Arm Label: Lacosamide; Type: EXPERIMENTAL; Interventions: Drug: Lacosamide | Arm Label: Carbamazepine-Controlled Release (CBZ-CR); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine-Controlled Release (CBZ-CR) | Intervention Type: DRUG; Name: Lacosamide; Assigned to Arm(s): Lacosamide | Intervention Type: DRUG; Name: Carbamazepine-Controlled Release (CBZ-CR); Assigned to Arm(s): Carbamazepine-Controlled Release (CBZ-CR)
D: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Oxcarbazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxcarbazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Oxcarbazepine; Assigned to Arm(s): Oxcarbazepine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Brief Summary: The purpose of this study is to determine whether BMS-936557 is effective for the treatment of moderate to severely active Crohn's Disease in patients who have had insufficient response and/or intolerance to conventional therapy for Crohn's Disease.


Options:
A: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg
B: Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Cohort 2: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 3: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Arm Label: Cohort 1: Open Label; Type: EXPERIMENTAL; Interventions: Drug: BMS-936557 (Anti-IP-10 Antibody) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Induction | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 2: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 3: Maintenance | Intervention Type: DRUG; Name: BMS-936557 (Anti-IP-10 Antibody); Assigned to Arm(s): Cohort 1: Open Label
C: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
D: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Citrasate Dialysate on Heparin Dose: A Randomized Cross Over Trial in Hemodialysis Patients.
Brief Summary: An alternative to systemic heparin anticoagulation for HD is citrate dialysate (CD). CD contains a small amount of citric acid rather than acetic acid as the acidifying agent. The use of citrasate may lead to lower heparin requirements in hemodialysis. This is a randomized, double blinded, two-period crossover trial in HD patients to compare the effect of citrasate dialysis (CD) and usual acetic-acid based dialysate (AD) on heparin dose.


Options:
A: Arm Label: PK Cohort; Type: EXPERIMENTAL; Interventions: Drug: ISIS 416858 | Arm Label: Cohort A; Type: PLACEBO_COMPARATOR; Interventions: Drug: ISIS 416858, Drug: Placebo | Arm Label: Cohort B; Type: PLACEBO_COMPARATOR; Interventions: Drug: ISIS 416858, Drug: Placebo | Intervention Type: DRUG; Name: ISIS 416858; Assigned to Arm(s): Cohort A, Cohort B, PK Cohort | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort A, Cohort B
B: Arm Label: AD- acetic acid dialysate; Type: ACTIVE_COMPARATOR; Interventions: Other: acetic-acid based dialysate (AD) | Arm Label: CD - citrasate dialysate; Type: EXPERIMENTAL; Interventions: Other: citrate dialysate (CD) | Intervention Type: OTHER; Name: citrate dialysate (CD); Assigned to Arm(s): CD - citrasate dialysate | Intervention Type: OTHER; Name: acetic-acid based dialysate (AD); Assigned to Arm(s): AD- acetic acid dialysate
C: Arm Label: EVODIAL dialyzer and Selectbag citrate; Type: EXPERIMENTAL; Interventions: Device: EVODIAL dialyzer and Selectbag citrate | Arm Label: Regional citrate anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Regional citrate anticoagulation | Intervention Type: DEVICE; Name: EVODIAL dialyzer and Selectbag citrate; Assigned to Arm(s): EVODIAL dialyzer and Selectbag citrate | Intervention Type: DEVICE; Name: Regional citrate anticoagulation; Assigned to Arm(s): Regional citrate anticoagulation
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: law molecular weigth heparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: unfractioned heparin | Intervention Type: DRUG; Name: law molecular weigth heparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: unfractioned heparin; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: euCPSP: European Observational Study on Chronic Post Surgical Pain,PAIN-OUT
Brief Summary: This project a European observational study on the incidence and characteristics of chronic post surgical pain (CPSP).

Research Questions

* What is the incidence of chronic post surgical pain (CPSP) in Europe?
* What are the risk factors of chronic post surgical pain (CPSP) related to surgery, patient and anaesthesia management?
* What are the difference in incidence and risk factors in different European countries?


Options:
A: Arm Label: Group I (Control); Type: PLACEBO_COMPARATOR; Interventions: Procedure: Erector Spinae Plan Block | Arm Label: Group II (ESP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Erector Spinae Plan Block | Arm Label: Group III(OSTAP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Oblique subcostal TAP | Intervention Type: PROCEDURE; Name: Erector Spinae Plan Block; Assigned to Arm(s): Group I (Control), Group II (ESP) | Intervention Type: PROCEDURE; Name: Oblique subcostal TAP; Assigned to Arm(s): Group III(OSTAP)
B: Arm Label: Erector Spinae (single injection); Type: EXPERIMENTAL; Interventions: Drug: Erector Spinae (single injection) | Arm Label: Paravertebral (single injection); Type: ACTIVE_COMPARATOR; Interventions: Drug: Paravertebral (single injection) | Intervention Type: DRUG; Name: Erector Spinae (single injection); Assigned to Arm(s): Erector Spinae (single injection) | Intervention Type: DRUG; Name: Paravertebral (single injection); Assigned to Arm(s): Paravertebral (single injection)
C: Arm Label: Patients; Type: N/A; Interventions: N/A
D: Arm Label: Erector Spinae Plane Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Erector Spinae Plane block, Drug: Bupivacaine Hydrochloride, Device: PCA | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham block, Device: PCA | Intervention Type: PROCEDURE; Name: Erector Spinae Plane block; Assigned to Arm(s): Erector Spinae Plane Block | Intervention Type: PROCEDURE; Name: Sham block; Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Bupivacaine Hydrochloride; Assigned to Arm(s): Erector Spinae Plane Block | Intervention Type: DEVICE; Name: PCA; Assigned to Arm(s): Control Group, Erector Spinae Plane Block

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: euCPSP: European Observational Study on Chronic Post Surgical Pain,PAIN-OUT
Brief Summary: This project a European observational study on the incidence and characteristics of chronic post surgical pain (CPSP).

Research Questions

* What is the incidence of chronic post surgical pain (CPSP) in Europe?
* What are the risk factors of chronic post surgical pain (CPSP) related to surgery, patient and anaesthesia management?
* What are the difference in incidence and risk factors in different European countries?


Options:
A: Arm Label: Patients; Type: N/A; Interventions: N/A
B: Arm Label: Therapeutic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: Prophylactic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Prophylactic, Therapeutic
C: Arm Label: Ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Treatment with Ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Arm Label: Treatment with Acetaminophen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetaminophen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Treatment with Ibuprofen | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): Treatment with Acetaminophen

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: euCPSP: European Observational Study on Chronic Post Surgical Pain,PAIN-OUT
Brief Summary: This project a European observational study on the incidence and characteristics of chronic post surgical pain (CPSP).

Research Questions

* What is the incidence of chronic post surgical pain (CPSP) in Europe?
* What are the risk factors of chronic post surgical pain (CPSP) related to surgery, patient and anaesthesia management?
* What are the difference in incidence and risk factors in different European countries?


Options:
A: Arm Label: Group I (Control); Type: PLACEBO_COMPARATOR; Interventions: Procedure: Erector Spinae Plan Block | Arm Label: Group II (ESP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Erector Spinae Plan Block | Arm Label: Group III(OSTAP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Oblique subcostal TAP | Intervention Type: PROCEDURE; Name: Erector Spinae Plan Block; Assigned to Arm(s): Group I (Control), Group II (ESP) | Intervention Type: PROCEDURE; Name: Oblique subcostal TAP; Assigned to Arm(s): Group III(OSTAP)
B: Arm Label: Erector Spinae Plane Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block | Arm Label: Serratus Anterior Plane Block; Type: EXPERIMENTAL; Interventions: Procedure: regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block | Intervention Type: PROCEDURE; Name: regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block; Assigned to Arm(s): Erector Spinae Plane Block, Serratus Anterior Plane Block
C: Arm Label: Patients; Type: N/A; Interventions: N/A
D: Arm Label: Erector Spinae (single injection); Type: EXPERIMENTAL; Interventions: Drug: Erector Spinae (single injection) | Arm Label: Paravertebral (single injection); Type: ACTIVE_COMPARATOR; Interventions: Drug: Paravertebral (single injection) | Intervention Type: DRUG; Name: Erector Spinae (single injection); Assigned to Arm(s): Erector Spinae (single injection) | Intervention Type: DRUG; Name: Paravertebral (single injection); Assigned to Arm(s): Paravertebral (single injection)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Life After STroke - the LAST Study. A Norwegian Multi Centre Randomized Controlled Trial
Brief Summary: The LAST study is a Norwegian multi site randomised controlled trial that intends to assess the effect of a long term follow up program after stroke. The program consists of a coordinating physiotherapist who will encourage and motivate included patients to perform at least 60 minutes of intensive motor training every week and 30 minutes of physical activity every day for 18 months after inclusion. The primary hypothesis is that patients receiving a long term follow up program after stroke will have better motor function at end of follow up than patients receiving standard care. A total of 390 home dwelling stroke patients living in the municipality of Trondheim, Asker and Bærum will be included at the out-patient clinic at St. Olavs Hospital or Bærum Hospital three months after their stroke. Included patients will be randomised to an intervention group receiving the long term follow up program or to a control group receiving standard care. Motor function, mental health and physical functioning in daily life will be assessed at inclusion and 18 months later. The LAST study is funded by the Norwegian Research Council, the Norwegian University of Science and Technology and the Central Norway Regional Health Authority and will conclude at the end of 2015.


Options:
A: Arm Label: Sitting; Type: EXPERIMENTAL; Interventions: Behavioral: Sitting | Arm Label: Standing; Type: EXPERIMENTAL; Interventions: Behavioral: Standing | Arm Label: Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Walking | Intervention Type: BEHAVIORAL; Name: Sitting; Assigned to Arm(s): Sitting | Intervention Type: BEHAVIORAL; Name: Standing; Assigned to Arm(s): Standing | Intervention Type: BEHAVIORAL; Name: Walking; Assigned to Arm(s): Walking
B: Arm Label: AARP; Type: N/A; Interventions: N/A
C: Arm Label: m-health stroke rehabilitation; Type: N/A; Interventions: Behavioral: Multimodal Exercise Rehabilitation Program | Intervention Type: BEHAVIORAL; Name: Multimodal Exercise Rehabilitation Program; Assigned to Arm(s): m-health stroke rehabilitation
D: Arm Label: Long term follow up program; Type: EXPERIMENTAL; Interventions: Behavioral: Long term follow up by a coordinating physiotherapist | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Long term follow up by a coordinating physiotherapist; Assigned to Arm(s): Long term follow up program | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care

Answer: D